Cure Ventures Management

Venture Capital Exempt reporting adviser

Legal name: Cure Ventures Management, LP

Boston, MA Website LinkedIn

AUM

$690.0M
Private fund assets

Private funds

2
Venture Capital 2

Private fund assets

$690.0M
Gross asset value

Employees

—

Last Form D raise

Dec 2025
Most recent fund filing

From SEC Form ADV filing (filed Mar 11, 2026). View on SEC

People(3)

Owners and executive officers named on the firm's SEC Form ADV.

D
David Fallace
Managing Partner
Source: SEC Form ADV
L
Louis Tartaglia
Managing Partner
Source: SEC Form ADV
R
Richard Lim
Managing Partner
Source: SEC Form ADV

Funds(2)

Private funds reported on Form ADV, with amounts raised from the funds' SEC Form D filings.

FundTypeGross assetsRaised (Form D)InvestorsLast Form DRecency
Cure Ventures Fund II, L.PVenture Capital$329.2M——Dec 2025Warm
Cure Ventures Fund I, L.P.Venture Capital$360.8M$350.5M44Apr 2023Cold

Board seats(1)

Companies whose SEC Form D filings name one of this firm's people as a director, matched by name and office ZIP code.

Tasca Therapeutics
BiotechnologyCambridge, MADirector: David Fallace
$48.1M raised
Since Nov 2024
SEC Form D

Regulatory identifiers

CRD number
315287
SEC file number
802-122147

Sources